Many cancers show upregulated COX expression and an unregulated conversion of arachidonic acid into bioactive prostaglandins. Previous research has shown that urinary PGE-M provides a way to measure this process. It is hoped that PGE-M may provide a marker for identifying individuals who following adenoma resection may be more likely to benefit from aspirin CRC […]
Long-term follow-up of the CAPP2 study demonstrates the benefits of daily aspirin for preventing hereditary colorectal cancer (Lynch syndrome) CAPP2 is an international, double-blind, randomised, placebo-controlled registry-based study of cancer prevention in people with Lynch syndrome. Lynch syndrome is a hereditary genetic condition which increases the person’s risk of developing certain cancers. The 10 year […]
Meta-analysis concludes that monotherapy with low-dose aspirin is comparable with P2Y12 inhibitor monotherapy for the secondary prevention of cardiovascular disease -confirming aspirin’s place as a cost effect drug of choice.
Chiarito and colleagues conducted a systematic review and meta-analysis of all randomised trials that compare P2Y12 inhibitors with low-dose aspirin monotherapy for the prevention of secondary cardiovascular (CV) events in patients with established cerebrovascular, coronary or peripheral artery disease with the aim of finding the optimal regimen. The researchers found nine trials with a total […]